Fuji Pharma Co., Ltd.

TSE:4554 Stock Report

Market Cap: JP¥37.7b

Fuji Pharma Valuation

Is 4554 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4554 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4554 (¥1561) is trading below our estimate of fair value (¥1700.59)

Significantly Below Fair Value: 4554 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4554?

Key metric: As 4554 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4554. This is calculated by dividing 4554's market cap by their current earnings.
What is 4554's PE Ratio?
PE Ratio6.2x
EarningsJP¥6.15b
Market CapJP¥37.66b

Price to Earnings Ratio vs Peers

How does 4554's PE Ratio compare to its peers?

The above table shows the PE ratio for 4554 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average14.5x
4548 Seikagaku
21.2xn/aJP¥42.9b
4577 Daito PharmaceuticalLtd
9.6x8.8%JP¥30.9b
4886 ASKA Pharmaceutical HoldingsLtd
9.8x2.0%JP¥58.1b
4569 KYORIN Pharmaceutical
17.3x-11.9%JP¥83.1b
4554 Fuji Pharma
6.2x-7.6%JP¥37.7b

Price-To-Earnings vs Peers: 4554 is good value based on its Price-To-Earnings Ratio (6.2x) compared to the peer average (14.5x).

Price to Earnings Ratio vs Industry

How does 4554's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
4554 6.2xIndustry Avg. 15.3xNo. of Companies7PE01020304050+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4554 is good value based on its Price-To-Earnings Ratio (6.2x) compared to the JP Pharmaceuticals industry average (15.3x).

Price to Earnings Ratio vs Fair Ratio

What is 4554's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4554 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio6.2x
Fair PE Ratio12.5x

Price-To-Earnings vs Fair Ratio: 4554 is good value based on its Price-To-Earnings Ratio (6.2x) compared to the estimated Fair Price-To-Earnings Ratio (12.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4554 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥1,561.00
JP¥2,285.00
+46.4%
12.5%JP¥2,570.00JP¥2,000.00n/a2
Dec ’25JP¥1,614.00
JP¥2,285.00
+41.6%
12.5%JP¥2,570.00JP¥2,000.00n/a2
Nov ’25JP¥1,292.00
JP¥2,085.00
+61.4%
4.1%JP¥2,170.00JP¥2,000.00n/a2
Oct ’25JP¥1,299.00
JP¥2,085.00
+60.5%
4.1%JP¥2,170.00JP¥2,000.00n/a2
Sep ’25JP¥1,359.00
JP¥2,085.00
+53.4%
4.1%JP¥2,170.00JP¥2,000.00n/a2
Aug ’25JP¥1,350.00
JP¥2,085.00
+54.4%
4.1%JP¥2,170.00JP¥2,000.00n/a2
Jul ’25JP¥1,478.00
JP¥2,085.00
+41.1%
4.1%JP¥2,170.00JP¥2,000.00n/a2
Jun ’25JP¥1,485.00
JP¥2,085.00
+40.4%
4.1%JP¥2,170.00JP¥2,000.00n/a2
May ’25JP¥1,596.00
JP¥2,090.00
+31.0%
6.1%JP¥2,270.00JP¥2,000.00n/a3
Apr ’25JP¥1,635.00
JP¥2,156.67
+31.9%
5.3%JP¥2,270.00JP¥2,000.00n/a3
Mar ’25JP¥1,703.00
JP¥2,156.67
+26.6%
5.3%JP¥2,270.00JP¥2,000.00n/a3
Feb ’25JP¥1,986.00
JP¥2,156.67
+8.6%
5.3%JP¥2,270.00JP¥2,000.00n/a3
Jan ’25JP¥1,739.00
JP¥2,135.00
+22.8%
6.3%JP¥2,270.00JP¥2,000.00n/a2
Dec ’24JP¥1,536.00
JP¥1,915.00
+24.7%
4.4%JP¥2,000.00JP¥1,830.00JP¥1,614.002
Nov ’24JP¥1,174.00
JP¥1,915.00
+63.1%
4.4%JP¥2,000.00JP¥1,830.00JP¥1,292.002
Oct ’24JP¥1,166.00
JP¥1,785.00
+53.1%
12.0%JP¥2,000.00JP¥1,570.00JP¥1,299.002
Sep ’24JP¥1,178.00
JP¥1,835.00
+55.8%
14.4%JP¥2,100.00JP¥1,570.00JP¥1,359.002
Aug ’24JP¥1,189.00
JP¥1,835.00
+54.3%
14.4%JP¥2,100.00JP¥1,570.00JP¥1,350.002
Jul ’24JP¥1,163.00
JP¥1,835.00
+57.8%
14.4%JP¥2,100.00JP¥1,570.00JP¥1,478.002
Jun ’24JP¥1,144.00
JP¥1,835.00
+60.4%
14.4%JP¥2,100.00JP¥1,570.00JP¥1,485.002
May ’24JP¥1,245.00
JP¥1,835.00
+47.4%
14.4%JP¥2,100.00JP¥1,570.00JP¥1,596.002
Apr ’24JP¥1,133.00
JP¥1,835.00
+62.0%
14.4%JP¥2,100.00JP¥1,570.00JP¥1,635.002
Mar ’24JP¥1,067.00
JP¥1,680.00
+57.5%
13.1%JP¥1,900.00JP¥1,460.00JP¥1,703.002
Feb ’24JP¥1,052.00
JP¥1,680.00
+59.7%
13.1%JP¥1,900.00JP¥1,460.00JP¥1,986.002
Jan ’24JP¥1,023.00
JP¥1,680.00
+64.2%
13.1%JP¥1,900.00JP¥1,460.00JP¥1,739.002
Dec ’23JP¥1,013.00
JP¥1,680.00
+65.8%
13.1%JP¥1,900.00JP¥1,460.00JP¥1,536.002

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:14
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fuji Pharma Co., Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yoshinaga ToshiakiAizawa Securities Co. Ltd.
Masao YoshidaIchiyoshi Research Institute Inc.
Shigekazu IshidaMarusan Securities Co. Ltd.